| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TXG | Class A Common Stock | Options Exercise | $80K | +6.97K | +2.45% | $11.48* | 291K | Aug 1, 2023 | Direct | |
| transaction | TXG | Class A Common Stock | Sale | -$107K | -1.73K | -0.59% | $61.77 | 289K | Aug 1, 2023 | Direct | F1, F2 |
| transaction | TXG | Class A Common Stock | Sale | -$327K | -5.24K | -1.81% | $62.36 | 284K | Aug 1, 2023 | Direct | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TXG | Stock Option (right to buy) | Options Exercise | $0 | -6.97K | -23.02% | $0.00 | 23.3K | Aug 1, 2023 | Class A Common Stock | 6.97K | $11.48 | Direct | F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2023. |
| F2 | This transaction was executed in multiple trades at prices ranging from $61.12 to $62.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F3 | This transaction was executed in multiple trades at prices ranging from $62.12 to $62.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F4 | All of the shares subject to the option are fully vested and exercisable as of the date hereof. |
President and Chief Scientific Officer